Truist notes Arcus Biosciences (RCUS) announced updated results from the Casdatifan monotherapy dose expansion study, including the pivotal 100mg QD cohort. The firm points out that the headline data for Casdatifan, particularly at the 100mg dose is trending to meet or beat the upper end of its expectations. Importantly, Truist notes a median progression free survival of 12 months is double that of its competitor. The firm has a Buy rating on the shares with a price target of $32.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences Presents Promising ARC-20 Study Data
- Arcus Biosciences announces new data for casdatifan
- Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study: Market Implications
- Gilead and Arcus Advance Promising Colorectal Cancer Study
- Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers